ROIV: Roivant Sciences Ltd. Company Short-Term Debt

Symbol and logo of brand Roivant Corp (ROIV)

Roivant Sciences Ltd. is developing a unique "Vants" model, acquiring undervalued assets for rapid implementation. The short-term debt assessment on this chart demonstrates liquidity, while 0.05 determines the latest valuation metric. The holding company is radically accelerating the market launch of anti-inflammatory drugs while remaining in an expansion phase. Massive cash reserves and a strong immunology pipeline serve as the primary growth drivers.

ROIV (Roivant) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Analytical breakdowns for Roivant Corp (ROIV)

- current quotes and average value forecast:
Price Chart Roivant Sciences|ROIV - Fair Value Consensus
- market capitalization information:
Market Value Roivant|ROIV - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Roivant Sciences|ROIV - Book Capitalization|Market Cap to Net Assets Ratio roivant.com|ROIV - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Roivant Sciences Ltd.|ROIV - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Roivant Sciences Ltd.|ROIV - Company Cumulative Debt|Debt to Book Capitalization Ratio Roivant|ROIV - Company Long-Term Debt|Company Short-Term Debts Roivant Sciences|Quick Ratio roivant.com
- net income and valuation multiples indicators:
ROIV - Net Financial Result
Basic company analysis:ROIV - Roivant Sciences
Manufactured products of Roivant Sciences Ltd.

Short-term debt measures the total obligations of Roivant Sciences Ltd. (ROIV) that require repayment within twelve months. In the biotechnology sector, such loans often fuel costly clinical trials. By analyzing the short-term debt trend, an investor can discern the balance between innovation investments and debt load. Since the business is insulated from economic cycles, risk is concentrated solely in FDA decisions. The stability of payments confirms the issuer's financial resilience.

Competitor analysis for Roivant Sciences Ltd.

LLY - Company Short-Term Debt|Company Short-Term Loans and Borrowings ABBV (AbbVie Inc)|AstraZeneca AB (AZN) - Company Short-Term Debt|Company Current Liabilities Novartis Pharma|MRK (Merck & Co., Inc.) - Company Short-Term Debts|Company Short-Term Debts novonordisk.com|Company Current Liabilities AMGN (Amgen)|PFE (Pfizer Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debts SNY (Sanofi Aventis)|Company Short-Term Loans and Borrowings BMY|GSK - Company Short-Term Debt|Short-Term Debt takeda.com|Teva Pharma (TEVA) - Company Short-Term Debt|RDY (Dr. Reddy's Laboratories Limited) - Company Short-Term Debt|VTRS (Viatris Corp) - Company Short-Term Debts|Company Short-Term Indebtedness ZLAB (Zai Lab Corp)|Company Short-Term Debts BHC|Short-Term Debt Volume cosmosholdingsinc.com